Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s42003-022-03094-5 http://scihub22266oqcxt.onion/10.1038/s42003-022-03094-5 35194132!8863895!35194132     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=35194132&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\35194132.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Commun+Biol 2022 ; 5 (1): 152 Nephropedia Template TP {{tp|p=35194132|t=2022. A synthetic protein as efficient multitarget regulator against complement over-activation |pdf=|usr=}}{{35194132}} gab.com Text A synthetic protein as efficient multitarget regulator against complement over-activation JO: Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=35194132 #FOAvip The complement system constitutes the innate defense against pathogens. Its dysregulation leads to diseases and is a critical determinant in many viral infections, e.g., COVID-19. Factor H (FH) is the main regulator of the alternative pathway of complement activation and could be a therapy to restore homeostasis. However, recombinant FH is not available. Engineered FH versions may be alternative therapeutics. Here, we designed a synthetic protein, MFHR13, as a multitarget complement regulator. It combines the dimerization and C5-regulatory domains of human FH-related protein 1 (FHR1) with the C3-regulatory and cell surface recognition domains of human FH, including SCR 13. In summary, the fusion protein MFHR13 comprises SCRs FHR1(1-2):FH(1-4):FH(13):FH(19-20). It protects sheep erythrocytes from complement attack exhibiting 26 and 4-fold the regulatory activity of eculizumab and human FH, respectively. Furthermore, we demonstrate that MFHR13 and FHR1 bind to all proteins forming the membrane attack complex, which contributes to the mechanistic understanding of FHR1. We consider MFHR13 a promising candidate as therapeutic for complement-associated diseases. Twit Text FOAVip A synthetic protein as efficient multitarget regulator against complement over-activation ????Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=35194132 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35194132 #FOAvip English Wikipedia <ref>{{Cite pmid|35194132}}</ref> A synthetic protein as efficient multitarget regulator against complement over-activation #MMPMID35194132 Ruiz-Molina N; Parsons J; Muller M; Hoernstein SNW; Bohlender LL; Pumple S; Zipfel PF; Haffner K; Reski R; Decker EL Commun Biol 2022[Feb]; 5 (1): 152 PMID35194132show ga The complement system constitutes the innate defense against pathogens. Its dysregulation leads to diseases and is a critical determinant in many viral infections, e.g., COVID-19. Factor H (FH) is the main regulator of the alternative pathway of complement activation and could be a therapy to restore homeostasis. However, recombinant FH is not available. Engineered FH versions may be alternative therapeutics. Here, we designed a synthetic protein, MFHR13, as a multitarget complement regulator. It combines the dimerization and C5-regulatory domains of human FH-related protein 1 (FHR1) with the C3-regulatory and cell surface recognition domains of human FH, including SCR 13. In summary, the fusion protein MFHR13 comprises SCRs FHR1(1-2):FH(1-4):FH(13):FH(19-20). It protects sheep erythrocytes from complement attack exhibiting 26 and 4-fold the regulatory activity of eculizumab and human FH, respectively. Furthermore, we demonstrate that MFHR13 and FHR1 bind to all proteins forming the membrane attack complex, which contributes to the mechanistic understanding of FHR1. We consider MFHR13 a promising candidate as therapeutic for complement-associated diseases. |*Complement Activation[MESH] |Amino Acid Sequence[MESH] |Animals[MESH] |Blood Proteins/*metabolism[MESH] |Bryopsida/genetics/metabolism[MESH] |COVID-19/epidemiology/metabolism/virology[MESH] |Complement Factor H/*metabolism[MESH] |Complement Membrane Attack Complex/metabolism[MESH] |Complement System Proteins/*metabolism[MESH] |Erythrocytes/*metabolism[MESH] |Humans[MESH] |Models, Molecular[MESH] |Pandemics/prevention & control[MESH] |Protein Binding[MESH] |Protein Conformation[MESH] |Recombinant Fusion Proteins/chemistry/genetics/*metabolism[MESH] |SARS-CoV-2/physiology[MESH]A synthetic protein as efficient multitarget regulator against complem(epmc).pdf DeepDyve Pubget Overpricing